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Abstract
Background: Primary care can play an important role in providing cardiovascular risk management in patients
with established Cardiovascular Diseases (CVD), patients with a known high risk of developing CVD, and potentially
for individuals with a low risk of developing CVD, but who have unhealthy lifestyles. To describe and compare
cardiovascular risk management, internationally valid quality indicators and standardized measures are needed. As
part of a large project in 9 European countries (EPA-Cardio), we have developed and tested a set of standardized
measures, linked to previously developed quality indicators.
Methods: A structured stepwise procedure was followed to develop measures. First, the research team allocated
106 validated quality indicators to one of the three target populations (established CVD, at high risk, at low risk)
and to different data-collection methods (data abstraction from the medical records, a patient survey, an interview
with lead practice GP/a practice survey). Secondly, we selected a number of other validated measures to enrich the
assessment. A pilot study was performed to test the feasibility. Finally, we revised the measures based on the
findings.
Results: The EPA-Cardio measures consisted of abstraction forms from the medical-records data of established
Coronary Heart Disease (CHD)-patients - and high-risk groups, a patient questionnaire for each of the 3 groups, an
interview questionnaire for the lead GP and a questionnaire for practice teams. The measures were feasible and
accepted by general practices from different countries.
Conclusions: An internationally standardized measure of cardiovascular risk management, linked to validated
quality indicators and tested for feasibility in general practice, is now available. Careful development and pilot
testing of the measures are crucial in international studies of quality of healthcare.
Background
Cardiovascular disease (CVD) is a major cause of pre-
mature death in Europe and also an important cause of
morbidity, contributing substantially to escalating
healthcare costs [1]. Cardiovascular risk management
(CVRM) is targeted at three broad populations: those
with established and diagnosed disease (e.g. angina,
stroke), those at high risk of developing CVD due to
known risk factors (e.g. hypertension, smoking), and
individuals at low risk for developing CVD, but with
unhealthy lifestyles. CVRM involves risk assessment and
communicating to patients the risk of developing CVD
[2,3], providing relevant guideline based treatments,
such as counselling on lifestyle as well as cardio-protec-
tive medication and follow-up where appropriate [4,5].
Primary care has an important role in the delivery of
CVRM and quality improvement programs have been
developed to further strengthen this role [6].
Previous research has emphasised the importance of
addressing global CVD risk assessment rather than
focusing on individual risk factors such as smoking [5].
Various global CVD risk assessment and communication
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instruments for use in primary care have been devel-
oped across Europe [7-12], but there are differential and
inconsistent use in routine clinical practice between and
within countries [13-15]. The EUROASPIRE studies
have advocated the need for more effective lifestyle
management of patients at high risk and medication
management of patients with coronary heart disease
(CHD) [16]. These findings were derived from patients
receiving treatment from medical specialists, whereas
most patients received treatment in primary care, parti-
cularly in countries with a strong primary care system
[17,18].
Quality indicators (QI) are used widely across Europe
and internationally as part of quality improvement and
pay-for-performance schemes [19-21], but research sug-
gests that not all patients received the necessary evi-
dence-based care that underpin these indicators [22,23].
We started a large project (EPA-Cardio) to assess
CVRM in primary care across Europe. The participating
countries were recruited from the TOPAS Europe Asso-
ciation, which is a collaboration between researchers of
quality improvement in healthcare, founded in January
2005 http://www.epa-cardio.eu. In the first stage of the
EPA-Cardio-project, we developed quality indicators for
the prevention and management of cardiovascular dis-
ease in primary care [24]. Careful development and test-
ing of measures linked to these quality indicators were
deemed crucial for valid international comparisons. This
paper describes the methods used to develop the set of
measures, the results of a pilot in different countries of
these measures, and the resulting final standardized
EPA-Cardio instrument.
Methods
The development of the data collection instruments and
piloting took place between March 2007 and January
2008. A core group of researchers (SC, MW, JvL, and
SL) developed the prototypes of the instruments, and
discussed and refined it in meetings with the project
partners. Pilot tests were done with GPs volunteering to
participate.
Development of the EPA-Cardio instrument
The EPA-Cardio instrument was developed by the pro-
ject partners of the EPA-Cardio project, from 9 Eur-
opean countries, Austria, Belgium, Finland, France,
Germany, Slovenia, Switzerland, the Netherlands and
the UK. The measures were linked to the previously
selected quality indicators (QI), using a modified Delphi
Technique with expert panels in each participating
country by a team, which was part of the first project
[22,23]. The expert panels rated a core set of 44 indica-
tors valid across 4 conceptual quality domains (lifestyle,
clinical processes and outcomes, organisation and
patient perspective). Furthermore, a broader set of addi-
tional 62 indicators had been rated “restricted valid”
with a lower level of agreement. We decided to include
these indicators in our study, because the core set
mainly reflected the secondary prevention in patients
with diabetes or established CVD, neglecting the pri-
mary prevention and patient perspective, which were
represented in the wider set (broad set). (Table 1)
The core group of researchers reviewed each of
the 106 indicators and made 2 decisions per indicator
(Figure 1): First, to which patient group was the indica-
tor relevant; and second to the recommended data col-
lection instruments. Indicators that were not applicable
to a certain patient group, representing rather organisa-
tional aspects in general, were allocated to “general
organisation” (table 1). As some quality of care-domains,
such as patient perspective, and the “primary-prevention
group” were under-represented in the quality indicator
set, a number of additional measures (not linked to the
quality indicators) were selected for subsequent
research. The instruments were developed and agreed in
a series of meetings between March and August 2007.
All project partners discussed their disagreements,
which led to several revisions of the instruments. The
resulting EPA-Cardio instrument was developed in Eng-
lish and translated into relevant languages using forward
and backward procedures [25].
Patient populations (table 2)
Patients with established/diagnosed CHD
Some indicators related to CVD overall, and others in
particularly to coronary heart disease (CHD). To facili-
tate data collection and homogenise our study group,
we decided to focus on the patient group to whom all
these indicators apply, i.e. patients with CHD. We
excluded patients with diabetes because our primary
focus was on patients with CVD.
Patients ‘at high risk’
While we used widely accepted risk-calculation models
to define high risk, for pragmatic reasons we defined
‘high risk’ for the EPA-Cardio pilot as a ‘male smoker
over 60 years of age. For these individuals (without
other risk factors), the risk of fatal or nonfatal CVD
events within 10 years was estimated at 14.4%, using a
German electronic risk calculation instrument [10],
meeting the definition-criteria of high risk. We expected
to facilitate patient sampling by focusing on one risk
factor other than age and gender.
Adults with unhealthy life styles
Only a few indicators related to this population. In EPA-
Cardio, we focused on all individuals between 18 and 45
years. As risk and risk factors for CVD increases with
age, we used this age limit with the intention of separat-
ing this group from patients at high risk of CVD.
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Patient samples
Data collection procedures differed between the partici-
pating countries, due to ethical and legal regulations,
and the number of available practice team members.
The research team provided guidance for patient sam-
pling and data collection as part of the EPA-Cardio
instrument.
Established CHD and ‘at high risk’ groups
In Germany, Slovenia, Switzerland, and the Netherlands,
patient selection and data extraction of the medical
record audit was conducted by a practice nurse (guided
by the GP). Support by telephone and email was pro-
vided by a researcher in the relevant country. In Bel-
gium, the GP took over this task, and, in the UK, a
Table 1 Allocation of the quality indicators (QI) - Data collection methods and patient groups
Data collection method Medical record audit Patient survey GP interview/practice survey overall number of QI
Quality of care domains* LS CP O PP LS CP O PP LS CP O PP
Patient groups
Patients with diabetes** 5
(4)
11
(3)
- - - 1
(0)
- - - - - - 17 (7)
Patients with CVD 5
(4)
18 (9) 1
(1)
- - 1
(0)
- 1
(0)
- - - - 26 (14)
Patient at high risk for CVD 3
(0)
20 (7) 1
(1)
- - - - - - - - - 24 (8)
Primary prevention group - - - - 2
(0)
3
(0)
1
(0)
- - - - - 6 (0)
Practice organisation - - - - - - - - - 18
(8)
15
(7)
- 33 (15)
Overall number of QI 13
(8)
49
(19)
2
(2)
0 2
(0)
5
(0)
1
(0)
1
(0)
0 18
(8)
15
(7)
0 106 (44)
* LS = Lifestyle; CP = Clinical processes; O = Organisational aspects; PP = Patient’s perspective.
** The group of patients with diabetes had been excluded in the study.
The numbers refer to the broad set of 106 quality indicators (QI) that were scored “restricted valid” with a lower level of agreement within all country panels.
The numbers in brackets refer to the core set of 44 quality indicators (QI), as part of the broad set, that were scored “valid” with a high level of agreement within
all country panels.
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Figure 1 The development of the EPA-Cardio instrument - a multi-stage process.
Ludt et al. BMC Health Services Research 2011, 11:70
http://www.biomedcentral.com/1472-6963/11/70
Page 3 of 10
researcher visited the practice to conduct the searches
and the audit in collaboration with practice staff.
Where there identified more than 30 patients in a
practice, we used random numbers to select patients for
inclusion. We included all identified patients where
there were less than 30 patients. We used consecutive
sampling if the practice conducted manual searches. All
patients selected for the medical audit (established CHD
and ‘at high risk’) per practice were included in the
patient survey (maximum of 30 patients per group per
practice). As in most countries (except the UK),
informed consent was requested for auditing medical
records, questionnaires with informed consent sheets
were sent after selecting eligible patients, and data were
abstracted only for those who had sent back written
consents. We intended to include at least 15 patients of
each group per practice.
Primary prevention group (aged 18-45)
It was planned to select the primary prevention group
by electronic searches (considering age group and exclu-
sion criteria) followed by random sampling of 40 indivi-
duals from the search list. Where an electronic search
was not feasible, the practice approached regular visitors
who met the inclusion criteria consecutively. As we
aimed to include 15 individuals per practice, we planned
to send 40 questionnaires per practice in cases of elec-
tronic selection, or to hand out 15 questionnaires to
practice visitors ready to participate in the study.
Measures
We allocated each indicator to the most appropriate
instrument: data abstraction forms for the medical
record for patients with CHD and patients at high risk
respectively, patient questionnaires for all 3 groups as
appropriate, an interview guide for the lead GP, and a
questionnaire for practice members. The designing of
the abstraction forms for the medical record followed
that of Banks [26], in order to facilitate data encoding
and analysis.
Questionnaire for patient survey
In all cases, selected patients were sent a questionnaire
and letter explaining the aims of the study along with an
informed consent sheet, a questionnaire (relevant to the
appropriate group), and a self-addressed prepaid envel-
ope to return the questionnaire to the research group
and the written consent sheet to the practice team. The
questionnaires included questions derived from the qual-
ity indicators, questions about sociodemographic issues
and other conditions. Validated instruments to evaluate
the quality of primary care from the patient perspective
were also included for all 3 patient groups [27]. Other
validated instruments were included to evaluate the qual-
ity of chronic care for patients with CHD [28-30] and
instruments to assess lifestyle behaviour for patients at
high risk and the primary prevention-group) [31-34].
Physician interview
A researcher conducted the interview with the lead GP or
practice manager, either by telephone or face to face and
recorded the answers in the interview questionnaire. The
interview questionnaire contained questions representing
indicators on organisational issues and risk assessment
methods. In addition, practice engagement in cardiovas-
cular quality improvement projects and public health
projects on cardiovascular health were assessed, and also
GP’s views and activities on primary prevention.
Practice questionnaire
Practice members completed a practice questionnaire
sent by the researchers. This questionnaire contained
questions to identify the practice according to size, loca-
tion, number and function of practice staff and number
of listed or yearly attending patients. Other items were
derived from the EPA practice management [35] and
represented the EPA dimensions “information process
and technology”, “organisation of chronic care and pre-
vention”, and “quality improvement”. These items were
included to obtain an insight into the quality manage-
ment activities of included practices considered to have
an influence on study results.
Table 2 Inclusion- and exclusion criteria for different patient groups
Patient groups 1. Patients with CHD 2. Patients at high risk 3. Primary-prevention group
Inclusion criteria: - Documented diagnosis - Men ≥ 60 and - Age: 18-45 years
- ICD 10 code: I20-I25 or - Smoker: - Registered or regular visitors in practice
- ICPC-2 code: K74-76 - ICD 10: F17 or
- ICPC-2: P17
Exclusion criteria for all 3 groups: - Diabetes
- terminal illness
- cognitive disorders (e.g. dementia)
- psychiatric diseases (e.g. schizophrenia)
- lack of language knowledge
Exclusion criteria for patient groups 2 and 3 - established CVD (Angina, Myocardial infarction, stroke)
Only the first two groups were included in the pilot study.
Ludt et al. BMC Health Services Research 2011, 11:70
http://www.biomedcentral.com/1472-6963/11/70
Page 4 of 10
Pilot study
The aim of the pilot study was to assess the acceptability
of the developed data collection instruments and feasibility
of the methods, irrespective of the difference of nationally
adapted methods. We conducted the pilot study at the
end of 2007 in 2 practices in 6 of the participating coun-
tries Belgium, Germany, the Netherlands, Slovenia, Swit-
zerland and the United Kingdom. Not all countries had
the materials translated and ready in time for the pilot
study. We focused only on patients with CHD and
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Figure 2 EPA-Cardio pilot study - flow chart.
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patients at high risk in the pilot, because most data-collec-
tion instruments and procedures were related to these
groups and the primary-prevention group was easier to
select. Researchers chose the practices out of national GP-
networks, approaching them by phone or mail. In each of
the participating countries, pilot practices received
between 100€ and 400€ as an incentive to take part.
All practices received a package with the study materi-
als prior to the researcher visit (UK), or conducting the
data collection in house (all other countries). This con-
sisted of instruction sheets, the flow chart (Figure 2),
questionnaires for patients, patient information, informed
consent sheets and questionnaires for the practice teams.
Data collection procedures included patient selection,
sending of patient questionnaires, data abstraction from
the medical records, interview with the lead GP and
completing of the practice questionnaire.
At the end of the pilot study, researchers interviewed the
lead nurse by phone (face-to-face in the UK at the time of
the visit), using an interview guide, and asked questions
about the acceptability and feasibility of the instruments as
well as the data-collection procedures. The pilot results
were discussed at a meeting of all EPA-Cardio country co-
ordinators, common standards were agreed, as also national
adaptations to revise the instruments and procedures for
subsequent use in the project. Ethical approval was sought
as appropriate in the different participating countries.
Results
The instrument was piloted in 12 European general
practices, 2 general practices per country, in Belgium,
Germany, the Netherlands, Slovenia, Switzerland and
the UK. These practices selected a total of 268 patients
with established CHD and 127 patients at high risk.
The practice teams rated study materials and instruc-
tions as easily understandable. Despite differences in
data-collection procedures between the countries, all
were capable of completing the assessment. It was possi-
ble to complete all procedures within 4-8 weeks. In the
UK, an external reviewer completed the assessment
within one working day per practice (without waiting
for the replies from the patient’s questionnaires).
Data-collection procedures
Selection of patient groups, data abstraction
The group of patients with CHD was easier to select
than the group of patients at high risk, because smoking
status was not well documented in the medical records,
and small practices could not select enough patients in
this group. Therefore, it was possible to identify 30
patients with CHD in most practices, whereas the num-
ber of patients selected at high risk was between 8 and
30 (in larger practices with patient lists of >10000
patients).
Patient Questionnaires
The patients had some difficulties in completing the
questionnaires, especially the PACIC-instrument, often
asking nurses for explanations. Patient lists were used as
check lists to follow the audit procedures, control the
questionnaire responses, and send a reminder if neces-
sary. Most of the countries sent reminders by mail. In
Germany, the practice nurses reminded patients by tele-
phone. Sending reminders was not permissible in the
UK. The response rates were between 50% (UK) and
100% (Slovenia).
Interview with the lead GP
The researcher carried out the interview with the lead
GP either in a face-to-face meeting (UK) or, in most
countries, by telephone. The interview lasted 15-20 min.
Questionnaire for the practice team
Practice teams had no problems with completing the
questionnaire for practice members. They needed 20-30
minutes to answer all questions.
Factors that contributed to the success or failure of data
collection
There was a good level of practice co-operation with the
research team of each country. Practices considered the
instructions for patient selection and data-collection
procedures as helpful, as well as the possibility to con-
tact the research team if problems arose with study pro-
cedures. The practices reported that the selection of the
eligible study patients from the medical records raised
the major problem and consumed the most time of the
audit. In most countries, nurses needed the help of the
GP because they were not familiar with ICD or ICPC
codes and searches run with the practice software.
The final EPA-Cardio instrument
Finally, researchers of 9 European countries developed
and agreed the final EPA-Cardio instrument (table 3).
The instrument consisted of 4 types of paper-based
instruments: abstraction forms to collect the data from
the medical records, an interview questionnaire for the
lead GP, patient questionnaires for 3 different patient
groups, and a questionnaire for practice teams. The
instrument included 74 quality indicators (37 core set
and 37 broad set) that were previously agreed in the
Delphi procedures. The main revisions in comparison to
the pilot instruments were changes to the definition of
the high-risk group to facilitate patient selection. We
finally defined this group by risk calculation with recom-
mended tools according to national guidelines, e.g. 10%
fatal CVD-risk as calculated by the Dutch risk tables or
by using a proxy measure: Patients with three out of the
following four risk factors hypertension, hypercholester-
olaemia, smoking and men over 60 years. The final
EPA-Cardio instrument included a questionnaire for the
primary-prevention group additionally. We also decided
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to apply to all the countries the PACIC-instrument that
had been used in only 4 countries (Austria, Germany,
the Netherlands and Switzerland) during the pilot. The
changes to the instruments had to be translated again.
Discussion
This study provided an internationally standardized
measure of cardiovascular risk management in primary
care, linked to previously selected quality indicators and
pilot tested for feasibility.
Strengths and limitations
The EPA-Cardio project was conducted by the same
team that developed the EPA-practice management
accreditation tool (European Practice Assessment). Les-
sons learned in the process were applied to EPA-Cardio
Table 3 The final EPA-Cardio instrument
Patients/Practice Instruments/Data content Number of items
Data abstraction tools
Patient groups*
1 and 2
- Sex and age - 2 items
- Quality indicators (QI) on documentation of: - 16 items for patient group 1
(18 QI)**
- Patient’s lifestyle (smoking, physical activity and BMI)
- lifestyle advice (smoking, physical activity and diet advice)
- levels of blood pressure, cholesterol and blood glucose
- 14 items for patient group 2
(12 QI)
Patient group 1 - QI on documentation of pharmaceutical treatment (statins, anti-platelet therapy and
influenza vaccination)
- 3 items (3 QI)
Interview guide
Lead GP - QI on documentation an medical record - 8 items (8 QI)
- QI on CVD risk assessment - 27 items (20 QI)
- Practice engagement in CVD-quality improvement (programs) or - 7 items (5 QI)
- Practice engagement in CVD-related public health programs+ - 1 item
- Views on primary prevention (lifestyle, lifestyle advice and support)+ - 11 items
Patient questionnaires
All patient groups:
1,2,3
- Patient demographics and conditions+ - 11 items
- Quality of primary care delivery (EUROPEP)+[27] - 23 items
Patient group 1 - QI on lifestyle advice and patient perspective - 2 items (2 QI)
- Quality of chronic illness care (PACIC)+ [28;29] - 26 items
Patient groups
1 and 2
- Quality of life / health state (EQ5D)+[51] - 5 items and VAS
- Medication/ Medication adherence (Morisky score) +[30] - 5 items
Patient groups
2 and 3
- Lifestyle: Rapid assessment of physical activity+ (RAPA) [32] - 14 items
- Lifestyle: Rapid Eating and Activity Assessment for participants - shortened version (REAP-S)
+[33]
- 16 items
- Lifestyle: Behavior Change Consortium: Smoking Assessment (Mid-Sized model - baseline
measurements)+[34]
- 10 items
Patient group 3 - Views on primary prevention (lifestyle, lifestyle advice and support) + - 11 items (6 QI)
Questionnaire for the practice team+
Practice team - Information process and technology - 11 items
- Organisation of chronic care and prevention - 20 items
- Quality improvement activities - 13 items
- Practice size and location - 5 items
- Practice staff (number and function) - 7 items
* Patient groups: 1 = Patients with CHD, 2 = Patients at high risk, 3 = Primary prevention group.
** The information in brackets refers to the number of quality indicators (QI) included.
+ Supplementary instruments.
VAS = Visual analogue scale.
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[35,36]. The basis of the EPA-Cardio instrument were
quality indicators developed using a validated Delphi
procedure. However, this methodology is did not cover
all aspects of cardiovascular prevention and care as
described and recommended in guidelines [20]. The
assessment of important activities of primary care, such
as communication, empathy, teamwork, consultation
time, counselling and continuity of care, require other
methodologies, such as in-depth interviews e.g. [37,38].
To complete the assessment of cardiovascular preven-
tion and management, we supplemented the EPA-Car-
dio instrument with patient evaluation instruments. We
therefore chose the EUROPEP-instrument because it is
validated, used in many surveys and exists in the lan-
guages of all participants [27]. As patients’ perspectives
contribute considerably to the improvement in the qual-
ity of care [39], we also included the PACIC instrument
to reflect the view of patients with established CHD
[28]. This project aims to provide better cover of pri-
mary prevention, and we therefore included validated
lifestyle-assessment instruments [31] and self-developed
questions on attitudes towards primary prevention for
individuals and GPs.
We included a convenience sample of countries out of
the TOPAS Europe Association http://www.topaseurope.
eu in the study for feasibility reasons and good experi-
ences with collaboration in past projects [35,36]. This
begs the question of whether EPA-Cardio be different if,
for example, Greece and Denmark and Portugal had
taken part in the study.
In the pilot, we used a small convenience sample of 2
practices in 6 of the 9 participating countries, as some
countries were not able to have the study materials
ready in time. The different methods used to select
patient groups may lead to different populations (with
limited generalisability) and different data-collection
procedures, and therefore may restrict the comparability.
The results of the subsequent observational study
should therefore be interpreted carefully.
Methods of data collection in general practices
The systematic collection of healthcare data across dif-
ferent countries in primary practice is difficult because
of differences in levels of computerisation and different
practice software within and between European coun-
tries [40]. The use of computers to record clinical data,
and also the content and quality of electronic patient
records, varies significantly [41,42]. In order not to
exclude countries or practices with lower levels of com-
puterisation, it is important to apply methodologies that
prevent research only from being conducted selectively
in technologically highly developed practices [22,43]. To
make data collection feasible for practices with different
technological levels in all countries, we developed
paper-based abstraction tools. However, electronic data
abstraction in general practice reduces the associated
workload and is a pre-condition for the implementation
of quality assessment in routine care [44].
The challenge of cross-national assessment
The aim of the study was to develop standardized data
collection procedures in all countries. However, it is also
necessary to adapt to differences in national procedures
to conduct cross-country collaborations. Perfect standar-
disation of data collection methods in cross-national
studies is not possible due to differences in legislation
and practice resources. For example, whether national
data protection acts allow anyone not employed by the
practice to look at patient medical records [45]. Another
difficulty is the different standards of the ethics commit-
tees between, and even within, countries [46,47]; for
example, in some countries practice staff are allowed to
collect patient data for quality improvement purposes
without the permission of patients (e.g. UK, the Nether-
lands), whereas in others (e.g. Germany, Belgium) the
informed consent of the patient is required.
The future of the EPA-Cardio instrument
We used the final EPA-Cardio instrument in the EPA-
Cardio project within 9 participating countries between
May 2008 and August 2009 [23]. The results of this
large observational study may be used to compare coun-
tries with different quality improvement strategies, such
as disease management programmes in Germany [48],
indicator-based incentive contracts in the UK [49], or
practice-based support with outreach visits in the Neth-
erlands [50]. This may identify best practice examples
and derive quality improvement recommendations for
the prevention and management of cardiovascular dis-
eases in Europe.
Conclusions
An internationally standardized measure of CVRM in
primary care is now available, linked to previously
selected quality indicators. It has been pilot tested for
feasibility. Careful development and pilot testing were
deemed crucial for international comparisons. Detailed
assessment, analysis and feedback can be the starting
point for developing quality improvement activities and
for deriving recommendations at a national and pan-
European level.
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